SCHILKE TOBIN (CFO) received a stock award from REVANCE THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 3/4/2024ACC: 0001479290-24-000051
Officer· CFO
Since Nov 2018
+17.45K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
17.45K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+17.45K
Price / share
—
Trade value
—
% of position
9.3%
2/29/2024
188.40K→205.85K
Total
Net shares
+17.45K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/29/2024 | A · Award | +17.45K | — | — | 9.3% | 188.40K | 205.85K |
| Total | +17.45K | $0.00 | ||||||
Derivative Transactions0
No derivative transactions reported